New insights into the mechanisms of action of radioimmunotherapy in lymphoma.
AffiliationSchool of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractThe exquisite sensitivity of haematological malignancies to targeted radiation alongside the impressive results achieved by the pioneers in this field suggests that radioimmunotherapy is likely to be a productive area for future clinical research. Recent experimental work has demonstrated that the combination of targeted radiation and antibody effector mechanisms are critical to long-term clearance of tumour. This review provides the background of clinical and biological insights into the mechanisms of action of radioimmunotherapy.
CitationNew insights into the mechanisms of action of radioimmunotherapy in lymphoma. 2008, 60 (8):987-98 J. Pharm. Pharmacol.
JournalThe Journal of Pharmacy and Pharmacology
- Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
- Authors: Hartmann Siantar CL, DeNardo GL, DeNardo SJ
- Issue date: 2003 Aug
- Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
- Authors: Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH
- Issue date: 2006 Feb
- Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
- Authors: Du Y, Honeychurch J, Glennie M, Johnson P, Illidge T
- Issue date: 2007 Feb 1
- Radioimmunotherapy with alpha-particle emitting radionuclides.
- Authors: Zalutsky MR, Pozzi OR
- Issue date: 2004 Dec
- Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
- Authors: Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM
- Issue date: 2009 Mar